Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets.  Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its product in the 8 mg, 12 mg, and 16 mg dosage strengths.
Under terms of the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to U.S. patents relating to Exalgo®.  Watson will have the right to launch its bioequivalent products on November 15, 2013.  Other details of the settlement were not disclosed.

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic version of Exalgo® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-h
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  InfuSystem Holdings, Inc. (NYSE MKT: INFU), a ... for the U.S. healthcare industry, today announced that it ... 12, 2015 after the market closes. The ... on Tuesday, May 12, 2015 at 4:30 p.m. Eastern ... participate in this call, please dial in toll-free 1-800-446-1671 ...
(Date:5/5/2015)... 2015  Omron Healthcare, Inc., the leader in home blood ... pressure monitor and scale with connectivity via smartphone, tablet, or ... With the population ... remote patient monitoring has become increasingly important for not only ... "These easy to use ...
(Date:5/5/2015)... May 5, 2015 Omeros Corporation (NASDAQ: ... discovering, developing and commercializing both small-molecule and protein ... targeting inflammation, coagulopathies and disorders of the central ... issue its first quarter 2015 financial results for ... May 11, 2015, after market close. Omeros management ...
Breaking Medicine Technology:New Blood Pressure Monitor And Scale Allow Chronically Ill Patients To Stay At Home While Connected To Healthcare Professionals 2New Blood Pressure Monitor And Scale Allow Chronically Ill Patients To Stay At Home While Connected To Healthcare Professionals 3Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015 2
... Inc. (Nasdaq: TNGN ), a leader in ... clinical assessment of the first implanted bladder cancer patient ... expected and has permitted the second patient to be ... trial calls for each of the first few patient ...
... A new white paper urges medical device and ... validation program as a means of preventing the ... terminally sterilized medical products are based on years of ... of failures occur due to inadequate package validation programs," ...
Cached Medicine Technology:Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients 2Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients 3New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 2New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 3
(Date:5/5/2015)... May 05, 2015 Buckeye Health Plan ... new CEO and plan president of Buckeye Health Plan. ... the position immediately. , Hill has more than 28 ... the Pacific Northwest, from managed care to large health ... and CEO of HealthPlus of Michigan, a health plan ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Igantia ... San Francisco, leads an international initiative to examine key ... extend the human lifespan. Scientists at Igantia believe ... women, from the initiation of her menstrual cycle to ... mechanism for aging and, ultimately, extend the lifespan. ...
(Date:5/5/2015)... 2015 HealthSlide, Inc ., ... solutions for hospitals nationwide, has announced the launch ... CIOs and CTOs can access the calculator on ... both initial and ongoing savings of switching to ... nation’s hospitals pay an average of $300,000 a ...
(Date:5/5/2015)... 05, 2015 After record-breaking sales of ... 2014, Walgreens introduces the Cookies & Cream flavor at ... Extend Nutrition has continually raised the bar for nutritional ... combined with an unprecedented nutritional profile, backed by international ... Extend Nutrition will launch additional new products and expand ...
(Date:5/5/2015)... May 05, 2015 Every year, news articles ... Turns out, the worst dry eye season is spring, also ... in most of the United States. The only season offering ... advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ Power ... her radio show of May 11, 2015. Kleyne is the ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... According to findings of a recent study researchers say bypass ... for many patients // with blocked heart arteries . ... on-pump (work of the heart is shifted to a mechanical ... still beating) surgery. Results of the surgeries were evaluated one ...
... in addition to medication show an improved clinical recovery ... to a new study. ,Researchers examined 126 patients ... in the middle cerebral artery. All the patients were ... of symptom onset. 63 patients were randomly assigned to ...
... cardiovascular disease risk factors, which include high blood pressure, impaired ... the condition is made if you have three out of ... risk for cardiovascular disease. According to a new study, starting ... add extra risk. ,Based on findings of the study ...
... and one of the most frequent causes of indigestion. Typical ... cases. Smoking and a high salt intake significantly increase the ... study. ,Results of the study showed that people ... 70-percent more likely to have acid reflux than non-smokers. Those ...
... more over several years puts one at greater risk for heart ... weight . ,Researchers studied nearly 2,500 adults between ages ... or more during the study, and 20 percent of these people ... and diabetes. But only 4 percent of those who didn't gain ...
... new study shows that not being in optimum cardiovascular health ... say researchers .// ,Researchers say they have found ... cognitive impairment in the elderly. The conditions of metabolic syndrome ... blood glucose levels, high blood pressure, and low levels of ...
Cached Medicine News:
Legionella IgG/M ELISA....
Measles IgM ELISA....
... The Wampole EBV ELISA test ... of assays for the determination ... tests for Viral Capsid Antigen ... Nuclear Antigen (EBNA). Most Wampole ...
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
Medicine Products: